Envu now carries the Alumis story
- Alumis has no commercial revenue yet, so the stock is mainly a bet on future drug approvals.
- Envudeucitinib, or envu, reported positive topline Phase 3 ONWARD results in plaque psoriasis in Q1 2026.
- The next key step is a planned FDA New Drug Application, or NDA, submission for envu in the second half of 2026.
- The ACELYRIN merger added assets and costs, but lonigutamab is now being reviewed for strategic alternatives.
- Because envu is the main value driver, an FDA setback would be a major hit to the business.
One drug leads the case
The bull case is simple. Envu is Alumis's lead TYK2 inhibitor, a drug meant to calm immune signaling in a more targeted way than broad immune-suppressing drugs. Positive topline Phase 3 ONWARD results in plaque psoriasis moved the story from trial readout risk toward filing and launch risk.
The next major catalyst is the planned New Drug Application, or NDA, for envu in plaque psoriasis in the second half of 2026. If the FDA accepts the filing and later approves the drug, Alumis can start moving from a research company toward a commercial one.
The bear case is also clear. Alumis is still pre-revenue, burns cash to run trials, and depends heavily on envu. The ACELYRIN merger added work, costs, and assets to sort through at the same time Alumis needs to stay focused on envu's filing.
Pipeline diversification also looks weaker than it did right after the merger. Alumis completed a review of lonigutamab in May 2026 and chose to explore strategic alternatives for that program. That puts more pressure back on envu and the upcoming SLE Phase 2 data.
Research first, sales later
Alumis does not sell approved drugs today. It spends investor capital on clinical trials, regulatory work, and drug development, with the goal of winning approvals and later earning revenue from drug sales or partnerships.
The company focuses on targeted immunology. That means it is trying to treat immune diseases by blocking specific signals, rather than using broad drugs that suppress large parts of the immune system.
Alumis does not own manufacturing plants. It relies on contract manufacturing organizations, called CMOs, to make clinical drug supply. That keeps fixed costs lower, but it adds dependence on outside partners for quality, timing, and scale.
The model breaks if envu is delayed, rejected, or cannot compete after approval. Before revenue arrives, Alumis must also keep funding trials and integration costs without letting dilution or cash pressure take over the story.
Pipeline built around TYK2
Envudeucitinib, or envu, in plaque psoriasis
This is the lead asset. It completed pivotal Phase 3 ONWARD1 and ONWARD2 trials, reported positive topline results in Q1 2026, and is planned for an NDA submission in the second half of 2026.
Envudeucitinib, or envu, in systemic lupus erythematosus
This is a Phase 2 use case for the same drug in lupus, an immune disease that can affect many organs. The expected Q3 2026 data could widen envu's value if it supports further study.
A-005
A-005 is an investigational CNS-penetrant TYK2 molecule, meaning it is designed to reach the central nervous system. It is earlier stage and remains a longer-term pipeline option.
Lonigutamab
Lonigutamab came from the ACELYRIN merger and targets IGF-1R for thyroid eye disease. Alumis completed a strategic review in May 2026 and is exploring strategic alternatives for the program.
One reported segment
Alumis reports one unified research and development operating segment and has generated no commercial revenue to date. The split below reflects that current business reality, with no product sales segment yet.
What could break it
Envu approval fails
High impact · Medium oddsEnvu is the main value driver. If the FDA rejects the planned plaque psoriasis NDA, asks for another major trial, or raises a safety issue, Alumis would lose its clearest path to first revenue.
Launch prep falls behind
High impact · Medium oddsPositive Phase 3 data does not by itself create a business. Alumis still needs regulatory execution, manufacturing supply, market access planning, and a commercial setup if envu is approved.
ACELYRIN integration drains focus
Medium impact · Medium oddsThe ACELYRIN merger brought added assets and integration costs. Those costs could distract management or consume capital while envu needs careful filing and launch preparation.
Pipeline breadth shrinks
Medium impact · High oddsLonigutamab was supposed to help diversify the pipeline after the merger. Alumis has now decided to explore strategic alternatives for the program, which means it may not remain a core asset.
Earlier trials disappoint
Medium impact · Medium oddsClinical failure risk is not theoretical. Alumis discontinued a Phase 2a envu trial in non-infectious uveitis in June 2024 after the efficacy results did not meet its threshold for success.
In one breath
Does Alumis have revenue?
No. Alumis is a clinical-stage biotech and has generated no commercial revenue to date. Its value depends on whether its drugs can win approval and later sell in the market.
What is envu?
Envudeucitinib, or envu, is Alumis's lead TYK2 inhibitor. It is being developed first for plaque psoriasis, where Alumis reported positive topline Phase 3 ONWARD results in Q1 2026.
What is the next big Alumis catalyst?
The next major company event is the planned envu NDA submission for plaque psoriasis in the second half of 2026. Investors are also watching Phase 2 SLE data expected in Q3 2026 and the outcome of the lonigutamab review.